

Special Issue

Latest Basic, Translational and Clinical Advancements in HER2-Positive Breast Cancer

Message from the Guest Editors

Breast cancer is one of the most common malignancies worldwide. Between 15% and 20% of breast cancers harbor HER2 overexpression and/or amplification, which is associated with an aggressive course of disease.

While results overwhelmingly demonstrate the clinical benefit of HER2-targeted therapy, a considerable number of patients do not benefit. Thus, advancements in an improved understanding of HER2-positive breast cancer biology, immunology, metabolism, genomics, and epigenetics, as well as the selection of more suited tailored treatments and predictive criteria of response to therapies, are still mandatory goals to be achieved. Indeed, HER2-driven cancer recurrence continues to be a real and significant clinical concern. This Special Issue will bring together expert researchers and physicians focusing on the latest key findings in the field of HER2-driven basic and translational research. It will also cover innovations in detection tools and treatment options of HER2-positive breast cancer.

Guest Editors

Dr. Serenella Pupa

Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, AmadeoLab, Via Amadeo 42, 20133 Milan, Italy

Dr. Elda Tagliabue

Head of Molecular Targeting Unit, Department of Research, AmadeoLab, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Amadeo 42, 20133 Milan, Italy

Deadline for manuscript submissions

closed (1 October 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/51414

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)